학생 감염병 예방교육(인플루엔자) 및 결핵예방교육

Scientific concepts & nature/health phenomena presented

Influenza (flu) in schools

Burden in schools (2019, Korea)

• Influenza ranked #1 among the “three major infectious diseases” monitored in elementary/middle/high schools.
• >330,000 students contracted influenza in 2019.
• >26,000 cases among high school students in a year.

History / terminology

• The influenza virus was first isolated in 1933.
• The 1918 Spanish flu was initially called “Spanish flu” (naming history context).
• 2009 swine flu (H1N1) is described as a new type of influenza and a major global event.

Virology (types of influenza viruses)

• Influenza virus is divided into three types: A, B, C.
• Type B
  • Typically milder symptoms
  • Infects humans
  • Mainly affects children
• Type A
  • Described as more dangerous
  • Linked to wild-life / pandemic risk
• Type A pandemics
  • Said to occur every 10–40 years

Seasonality / spread pattern

• “Seasonal influenza” is commonly prevalent winter to spring (also linked to conditions mentioned as reduced water sources in the subtitles).
• Spread is associated with the coughing season, with more cases during winter.

Symptoms (clinical picture)

• Sudden systemic symptoms: high fever, headache, muscle pain, fatigue.
• Respiratory symptoms: cough, sore throat; cough may persist >1 week.
• Complication warning signs: persistent high fever + cough + yellow phlegm + shortness of breath → suspect pneumonia.
• Typical recovery: most recover within about one week after symptom onset.

Distinguishing flu vs common cold

• Flu is sometimes called a “severe cold,” but key differences include:
  • Sudden onset for flu, often with high fever (30–41°C range claimed), and a less clearly defined start time.
  • Common cold onset is more gradual, with low-grade fever and less clearly defined start.
• Different causes (viral diversity)
  • Common cold: 100+ viruses (e.g., rhinoviruses, coronaviruses)
  • Flu: caused by influenza virus (single virus family/type)
• Therefore, flu vaccine does not prevent the common cold.

Transmission mechanisms (how it spreads)

• Primarily via respiratory droplets from coughing/sneezing.
• Droplets generally travel within about ~1 meter (as claimed in the subtitles).
• Enclosed, poorly ventilated spaces (e.g., classrooms) can enable broader spread and clustered outbreaks.
• Virus survival: stated to persist for several hours even in dry conditions.
• Possible indirect spread: contact with contaminated items (clothes, bedding, money) → then transmission via hands.

Infectious period

• Infectiousness begins on the day symptoms start or the day before.
• Virus can spread for up to ~7 days if symptoms persist.

Diagnosis methods

• Nasal swab test
• PCR testing
• Rapid antigen test for immediate on-site confirmation

Prevention: vaccination + hygiene (compared to COVID-19 practices)

• Most effective: annual influenza vaccination
• Also emphasized:
  • Hand washing
  • Cough etiquette
  • Mask wearing
• Vaccination timing
  • Get vaccinated at least 2 weeks before flu season (immunity takes >2 weeks to develop)
  • Effect lasts about 6 months
  • Latest recommended time: by mid-November
• Vaccine effectiveness (as stated)
  • About 80% overall
  • Closer to ~60% for elderly/children
  • Can drop when variants are circulating
• Even with vaccination
  • Infection can still occur if vaccine strain and circulating strain don’t match
  • Vaccine selection is described as WHO-driven annually
  • Influenza mutates continuously → re-vaccination each year is necessary
  • Two different influenza viruses can circulate yearly → possibility of infection twice in one season

Vaccine side effects

• “Blenza vaccine” mentioned as having relatively fewer side effects.
• Common: injection-site pain/redness in ~15–20%, usually resolves within 1–2 days
• Rare: systemic reactions including anaphylaxis (very low frequency)

---

Tuberculosis (TB) prevention/education

Disease history / discovery context

• TB is described as an “old-fashioned” disease but still causing outbreaks.
• Believed TB traces appeared when humans began raising livestock.
• TB traces found in Egyptian mummies dating ~6,000 years ago (as stated).

Epidemiology (Korea and global context, as stated)

• TB incidence and mortality decreased due to:
  • Isolation/quarantine
  • Treatments
  • Improved living conditions
• TB remains common in impoverished regions (Asia, Africa, Latin America).
• In Korea:
  • Incidence and mortality decreased with improved hygiene/nutrition, but
  • New cases continue steadily
  • Korea has the highest incidence/mortality among OECD member countries (as stated).
• Numbers mentioned (subtitles’ figures): over 23,000 new TB cases and ~1,500 deaths in the cited period.

Etiology / organism

• TB is caused by Mycobacterium tuberculosis.
• Can be:
  • Pulmonary TB (lungs)
  • Extrapulmonary TB (other organs)

Transmission mechanism

• Spread occurs via inhalation of bacteria in tiny droplets from untreated active pulmonary TB patients when coughing/speaking.
• Higher risk in enclosed spaces (classrooms) due to saliva concentration.
• Infection outdoors is said to be rare.
• After starting appropriate treatment, infectiousness significantly decreases about 2 weeks after treatment begins.

Active vs inactive (latent) TB

• Active TB
  • Bacteria multiply/spread
  • “Tuberculosis” in the classic sense
  • Treatment required
• Inactive/latent TB
  • Bacteria remain but lose vitality
  • No active transmission
  • Described as not requiring treatment

Contagion risk after close contact (as stated)

• About 30% of close contacts become infected.
• Of those infected:
  • 10% develop disease soon (immediately after infection, as stated)
  • 90% become “latent”
• Among latent cases:
  • 50% develop disease within 1–2 years
  • 50% may develop disease later in life (with ~10% potential active TB before death, as stated)

Symptoms and misdiagnosis vs COVID-19

• TB symptoms include cough plus:
  • phlegm
  • fever
• Similarity to COVID-19: both can be associated with cough and droplet spread.
• Key distinction: TB is chronic (long duration of symptoms).

Symptom timeline (as stated)

• Early infection:
  • May have no symptoms or only mild symptoms (fever, malaise).
• Symptoms last >3 months before worsening is recognized.
• Later possible signs:
  • persistent cough, wheezing, shortness of breath
  • skin abnormalities, joint pain
  • severe lung damage/fluid accumulation → breathlessness >2 weeks
  • hemoptysis: coughing up sputum with blood
  • weight loss for >3 months despite normal intake

Asymptomatic infection (latent TB)

• Called latent tuberculosis infection
• No symptoms and not transmitted to others while latent.
• Can transition to active TB later, potentially causing outbreaks within families or schools.

School-focused prevention strategy

• Priorities:
  • Rapid identification of infected students
  • Prompt treatment
• High infectivity is “immediately before treatment.”
• After taking drugs, infectiousness drops quickly.
• After 2 weeks, treated patients are no longer infecting others (as stated).

BCG vaccination

• To prevent severe TB in newborns:
  • BCG vaccination within one month of birth

Behavioral respiratory hygiene for preventing spread

• Use disposable tissue to wipe nose/mouth; dispose in trash.
• Wear a mask during the period of transmission.
• If no tissue: cough/sneeze into the inner elbow/forearm (rather than hands).

Multidrug-resistant TB (MDR-TB)

• Defined as TB resistant to multiple drugs.
• Resistance specifically mentioned for:
  • isoniazid
  • rifampin
• Treatment duration is longer and success rate is low.
• Emphasized: treating the first infection well is important.
• Some cases transmit MDR-TB bacteria already, so MDR-TB can appear from the first infection.

---

Researchers or sources featured (as named in subtitles)

• Professor Lee Jae-gap (Department of Infectious Diseases, Hallym University Kangnam Sacred Heart Hospital)
• Ministry of Education (Korea) — school infectious disease surveillance statistics (2019)
• WHO (World Health Organization) — annual selection of influenza vaccine strains for vaccine production